Lannett Company, Inc. (LCI) Shares Bought by Affinity Investment Advisors LLC
Affinity Investment Advisors LLC lifted its position in Lannett Company, Inc. (NYSE:LCI) by 16.1% in the 2nd quarter, Holdings Channel reports. The firm owned 29,501 shares of the company’s stock after purchasing an additional 4,092 shares during the quarter. Affinity Investment Advisors LLC’s holdings in Lannett were worth $401,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new position in shares of Lannett in the first quarter worth about $139,000. Virginia Retirement Systems ET AL purchased a new position in shares of Lannett in the first quarter worth about $181,000. Quantbot Technologies LP raised its stake in shares of Lannett by 473.7% in the first quarter. Quantbot Technologies LP now owns 12,368 shares of the company’s stock worth $198,000 after purchasing an additional 10,212 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Lannett in the second quarter worth about $168,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Lannett in the fourth quarter worth about $295,000.
Shares of LCI stock opened at $13.55 on Tuesday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.56 and a quick ratio of 1.91. The company has a market cap of $515.09 million, a P/E ratio of 4.74 and a beta of 2.44. Lannett Company, Inc. has a twelve month low of $11.90 and a twelve month high of $30.35.
In related news, VP Kevin Smith sold 11,667 shares of Lannett stock in a transaction that occurred on Thursday, June 14th. The stock was sold at an average price of $16.51, for a total transaction of $192,622.17. Following the completion of the transaction, the vice president now directly owns 30,125 shares in the company, valued at $497,363.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.72% of the stock is currently owned by company insiders.
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages.
Recommended Story: How to Track your Portfolio in Google Finance
Want to see what other hedge funds are holding LCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lannett Company, Inc. (NYSE:LCI).
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.